<DOC>
	<DOCNO>NCT01498692</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness PROMUS Element™ Everolimus-Eluting Coronary Stent System treatment patient 2 de novo atherosclerotic coronary artery lesion . The lesion locate vessel small average-sized .</brief_summary>
	<brief_title>The PLATINUM Clinical Trial Assess PROMUS Element Stent System Treatment De Novo Coronary Artery Lesions Small Vessels</brief_title>
	<detailed_description>The wide-spread use drug-eluting stent ( DES ) evolve standard care de novo lesion . The propose study evaluate safety effectiveness PROMUS Element treatment de novo atherosclerotic lesion native coronary artery . The study design consistent draft guidance industry title , `` Coronary Drug-Eluting Stents - Nonclinical Clinical Studies '' ( March 2008 ) . During trial , thienopyridines must administer accord 2007 American College Cardiology ( ACC ) /American Heart Association ( AHA ) /Society Cardiovascular Angiography Interventions ( SCAI ) guideline , recommend clopidogrel ( 75 mg daily ) ticlopidine ( 250 mg twice daily ) prescribe stent implantation least 6 month patient , least 12 month patient high risk bleeding . For site United States , use prasugrel allow part PLATINUM Clinical Trial . For sites country , prasugrel may prescribe accord approved dosing country available . For patient take aspirin daily load dose recommend ; patient take aspirin daily , aspirin must administer load dose . Patients continue take aspirin indefinitely reduce risk thrombosis . This PLATINUM Small Vessel study sub-trial associate PLATINUM Workhorse Randomized Controlled Trial , register NCT00823212 .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must least 18 year age Patient ( legal guardian ) understand study requirement treatment procedure provide write informed consent studyspecific test procedure perform For patient le 20 year age enrol Japanese site , patient patient 's legal representative must provide write informed consent studyspecific test procedure perform Patient eligible percutaneous coronary intervention ( PCI ) Patient document stable angina pectoris document silent ischemia ; unstable angina pectoris Patient acceptable candidate coronary artery bypass grafting ( CABG ) Patient leave ventricular ejection fraction ( LVEF ) &gt; =30 % measure within 30 day prior enrollment Patient willing comply protocolrequired followup evaluation Angiographic Inclusion Criteria ( visual estimate ) : Target lesion must de novo lesion locate native coronary artery visually estimate reference vessel diameter ≥2.25 mm &lt; 2.5 mm . Target lesion length must measure ≤28 mm visual estimate . Target lesion must locate major coronary artery branch visually estimate stenosis ≥50 % &lt; 100 % Thrombolysis In Myocardial Infarction ( TIMI ) flow &gt; 1 . Patient clinical symptom and/or electrocardiogram ( ECG ) change consistent acute myocardial infarction ( MI ) Patient know diagnosis recent MI ( ie , within 72 hour prior index procedure ) elevate enzymes time index procedure follow . Patients exclude follow criterion meet time index procedure . If creatine kinasemyoglobin band ( CKMB ) &gt; 2× upper limit normal ( ULN ) , patient exclude regardless CK Total . If CKMB 12× ULN , patient exclude CK Total &gt; 2× ULN . If CK Total/CK MB use Troponin , patient exclude follow criterion meet time index procedure . Troponin &gt; 1× ULN least one follow . Patient ischemic symptom ECG change indicative ongoing ischemia ( eg , &gt; 1 mm ST segment elevation depression consecutive lead new left bundle branch block [ LBBB ] ) ; Development pathological Q wave ECG ; Imaging evidence new loss viable myocardium new regional wall motion abnormality . Note : For patient unstable angina patient recent MI , CK Total/CK MB ( Troponin CK Total/CK MB use ) must document prior enrolling/randomizing patient . Patient receive organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy within 30 day index procedure Patient receive oral intravenous immunosuppressive therapy ( ie , inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( eg , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) Patient receive chronic ( &gt; =72 hour ) anticoagulation therapy ( eg , heparin , coumadin ) indication acute coronary syndrome Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 Patient white blood cell ( WBC ) count &lt; 3,000 cells/mm3 Patient document suspect liver disease , include laboratory evidence hepatitis Patient dialysis know renal insufficiency ( ie , estimate creatinine clearance &lt; 50 ml/min Cockcroft Gault formula , [ ( 140age ) *lean body weight ( kg ) ] / [ plasma creatinine ( mg/dl ) *72 ] ) Patient history bleed diathesis coagulopathy refuse blood transfusion Patient cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month , permanent neurologic defect may cause noncompliance protocol Target vessel ( ) side branch treat type PCI ( eg , balloon angioplasty , stent , cut balloon , atherectomy ) within 12 month prior index procedure Target vessel ( ) treat within 10 mm proximal distal target lesion ( visual estimate ) type PCI ( eg , balloon angioplasty , stent , cut balloon , atherectomy ) time prior index procedure Nontarget vessel side branch treat type PCI ( eg , balloon angioplasty , stent , cut balloon , atherectomy ) within 24 hour prior index procedure Planned actual target vessel ( ) treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter immediately prior stent placement Planned PCI CABG index procedure Patient previously treat time coronary intravascular brachytherapy Patient know allergy study stent system protocolrequired concomitant medication ( eg , stainless steel , platinum , cobalt , chromium , nickel , tungsten , acrylic , fluoropolymers , everolimus , thienopyridines , aspirin , contrast ) adequately premedicated Patient active peptic ulcer active gastrointestinal ( GI ) bleed Patient one following . Other serious medical illness ( eg , cancer , congestive heart failure ) may reduce life expectancy le 24 month Current problem substance abuse ( eg , alcohol , cocaine , heroin , etc . ) Planned procedure may cause noncompliance protocol confound data interpretation Patient participate another investigational drug device clinical trial reach primary endpoint Patient intend participate another investigational drug device clinical trial within 12 month index procedure Patient know intention procreate within 12 month index procedure ( Women childbearing potential sexually active must agree use reliable method contraception time screen 12 month index procedure . ) Patient woman pregnant nursing ( A pregnancy test must perform within 7 day prior index procedure woman childbearing potential ) Patient 2 target lesion , 1 target lesion 1 nontarget lesion , treat index procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>DES</keyword>
	<keyword>atherosclerotic</keyword>
</DOC>